A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities

BACKGROUND: The efficacy of epidermal growth factor (EGF) receptor (EGFR) inhibitors in patients with non‐small cell lung cancer (NSCLC), pancreatic cancer (PC), or colorectal cancer (CRC) has been demonstrated. However, dermatological reactions to these inhibitors can cause significant physical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Young Saing, Ji, Jun Ho, Oh, Sung Yong, Lee, Suee, Huh, Seok Jae, Lee, Ji Hyun, Song, Ki‐Hoon, Son, Choon Hee, Roh, Mee Sook, Lee, Gyeong Won, Lee, Jeeyun, Kim, Seung Tae, Kim, Chan Kyu, Jang, Joung Soon, Hwang, In Gyu, Ahn, Hee Kyung, Park, Lee Chun, Oh, So Yeon, Kim, Seong‐Geun, Lee, Sang‐Cheol, Lim, Do‐Hyoung, Lee, Soon Il, Kang, Jung Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964120/
https://www.ncbi.nlm.nih.gov/pubmed/31492766
http://dx.doi.org/10.1634/theoncologist.2019-0221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964120/
https://www.ncbi.nlm.nih.gov/pubmed/31492766
http://dx.doi.org/10.1634/theoncologist.2019-0221

Ejemplares similares